Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14.8% | 10.7% | 8.1% |
| 2025 | 2024 |
|---|---|
| 10.0% | 31.4% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14.8% | 10.7% | 8.1% |
| 2025 | 2024 |
|---|---|
| 10.0% | 31.4% |
The Driehaus Small/Mid Cap Growth strategy returned 1.75% in Q4 2025, outperforming the Russell 2500 Growth Index by 142 basis points. The core thesis centers on small cap earnings acceleration and expected outperformance versus large caps. Small caps have rallied 42.4% from April lows, driven by improving fundamentals and earnings growth that is expected to eclipse large cap growth through 2026. AI continues as the dominant market theme, driving capex spending and productivity gains that support economic expansion. Healthcare was the top contributing sector, benefiting from positive biotech clinical trials and approvals. The strategy increased healthcare exposure to 23.1% while reducing technology exposure due to software weakness. Key risks include AI's impact on employment, geopolitical tensions, and potential data center construction delays. However, the outlook for 2026 remains bullish given economic expansion, strong earnings, fiscal stimulus, and monetary easing. The broadening market participation across sectors reinforces conviction that small caps are entering 2026 with durable momentum and favorable risk-reward profiles.
Small and mid-cap growth companies are positioned for outperformance as small cap earnings accelerate and are expected to outgrow large cap earnings, while AI-driven productivity gains and economic expansion support a favorable investment environment.
Looking into 2026, we view the market outlook as positive. The US is currently experiencing economic expansion, strong earnings, stable long-term interest rates, fiscal stimulus, and monetary easing. We believe the outlook for 2026 is bullish with key macro drivers remaining intact.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 14 2026 | 2025 Q4 | CRNX, CVNA, GH, NTRA, PWR, XBI | AI, Biotechnology, energy, growth, healthcare, industrials, small caps, technology | - | AI continues to be the dominant theme driving the market and economy. Demand for AI LLMs is going up exponentially, with demand by AI users… |
| Oct 14 2025 | 2025 Q3 | - | Artificial Intelligence, Capex, energy, industrials, Utilities |
AXON US PWR US CVNA US GH US |
The strategy emphasizes AI-driven hyperscaler and utility capex as structural tailwinds for small/mid-cap growth. Robust earnings and Fed easing have supported broad-based equity rallies, with… |
| Jul 11 2025 | 2025 Q2 | - | AI, growth, infrastructure, small caps | - | - |
| Apr 17 2025 | 2025 Q1 | - | - | - | - |
| Jan 17 2025 | 2024 Q4 | - | - | - | - |
| Oct 11 2024 | 2024 Q3 | - | - | - | - |
| Jul 28 2024 | 2024 Q2 | - | - | - | - |
| Apr 27 2024 | 2024 Q1 | - | - | - | - |
| Jan 17 2024 | 2023 Q4 | - | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
Data CentersSupply constraints curtailing infrastructure buildout rate, but compute capacity is being used immediately upon coming online. This differs from dot-com bubble when dark fiber was installed ahead of need. Labor, power and land shortages creating bottlenecks. |
Supply Constraints Utilization Bottlenecks Infrastructure | |
EnergyEnergy plays a critical role in AI infrastructure economics, with data centers becoming major electricity consumers. Rising power costs compress margins while grid constraints and regulatory scrutiny influence deployment timelines. The manager emphasizes that unlike software-driven growth, AI compute cannot be scaled independently of physical energy reality. |
Data Centers Grid Power Infrastructure Utilities | |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
TechnologyThe fund added three technology companies that have each halved over 2025 and hopes to add more. Many tech stocks had become expensive but recent falls present opportunities, though most still aren't cheap enough including Xero. |
Software Valuation Opportunity Selloff | |
| 2025 Q3 |
AI Capex |
|
Industrial Growth |
||
UtilitiesThe utilities sector led returns in Q4 2025, with SSE delivering strong performance supported by its upgraded investment plan and improved visibility across regulated earnings and renewable infrastructure growth. The portfolio maintains an 8.9% allocation to utilities, representing a +5.3% overweight versus the benchmark. |
Regulated Utilities Renewable Infrastructure Investment Plan Earnings Visibility Infrastructure | |
| 2025 Q2 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2025 | Fund Letters | Jeffrey James | AXON US | Axon Enterprise, Inc. | Industrials | Aerospace & Defense | Bull | NASDAQ | cloud, Defense, growth, law enforcement, Margins, recurring revenue, SaaS | Login |
| Oct 14, 2025 | Fund Letters | Jeffrey James | PWR US | Quanta Services, Inc. | Industrials | Engineering & Construction | Bull | NYSE | backlog, Electrification, energy, Grid, growth, infrastructure, Margins | Login |
| Oct 14, 2025 | Fund Letters | Jeffrey James | CVNA US | Carvana Co. | Consumer Discretionary | Internet & Direct Marketing Retail | Bull | NYSE | Autos, cash flow, ecommerce, growth, leverage, restructuring, valuation | Login |
| Oct 14, 2025 | Fund Letters | Jeffrey James | GH US | Guardant Health, Inc. | Health Care | Diagnostics & Research | Bull | NASDAQ | Adoption, Biotech, diagnostics, FDA, growth, Oncology, Reimbursement | Login |
| TICKER | COMMENTARY |
|---|---|
| CRNX | Crinetics Pharmaceuticals Inc Health Care 2.0 |
| CVNA | Our portfolio looks very skewed to Carvana, but that is a feature of the strategy – to let winners run. We did not buy Carvana at this size; it is this size because it is up 100x from its 2022 lows. Carvana uses its technology to manage pricing, logistics, inspections, reconditioning workflow, merchandising, and more. These are all cogs in the industrial machine it has assembled to buy and sell cars to end customers. Significant proprietary technology has been developed to enable Carvana's retail and wholesale operations. Because Carvana is digitally native and has significant size and scale, it has been able to invest in significantly more technology than other auto dealers. |
| GH | Guardant Health, a provider of blood-based diagnostic tests for cancer, performed particularly well, driven by strong Q3 results. Its core oncology business grew revenues 30% vs. 20% in the previous quarter, an acceleration driven by innovative product enhancements. Furthermore, its colon cancer screening tests continued to perform well, growing 50% sequentially from Q2. While shares were up significantly in 2025, we remain bullish on the business, as Guardant continues to lead the charge in converting oncology testing from tissue to blood. |
| NTRA | Not owning Natera, Inc. (NTRA) detracted from performance. The stock rose after its earnings announcement, signaling a strong revenue beat. |
| PWR | Quanta Services is a leading infrastructure solutions provider for electric power, renewable energy and telecommunications. The company is a key enabler of electrification and grid modernization with a long runway for growth. |
| XBI | the biotech ETF (SPDR S&P Biotech- XBI) is making a new four year high |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||